VC insiders inject $16M into Chimerix

With an experimental antiviral in mid-stage clinical trials, Research Triangle Park, NC-based Chimerix has raised $16.1 million from a Series E. Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company participated in this insider round.

Much of that money is earmarked for further development of CMX001, a broad-spectrum antiviral in Phase II for cytomegalovirus (CMV) and BK virus. CMX001 is also being studied as a possible treatment for smallpox. And Chimerix is planning to push the anti-HIV therapy CMX157 into Phase I.

"These funds will enable us to drive forward clinical development of our promising drug candidates to a point where we are well-positioned to make strategic decisions about the best course for late-stage clinical development, as well as potential partnering with leading pharmaceutical companies," said Chimerix CEO George Painter, Ph.D.

- check out the Chimerix release

Suggested Articles

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.